ArticleThe Journal of dermatology2026
Recurrence Patterns and Prognostic Factors in Sentinel Lymph Node-Negative Melanoma in a Taiwanese Cohort With Predominant Acral Melanoma.
Article in The Journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cutaneous melanoma in Asian populations is characterized by a predominance of acral melanoma and distinct clinicopathologic features. Although sentinel lymph node biopsy (SLNB) is widely used for staging, a subset of SLN-negative patients still develop recurrence, and evidence regarding recurrence patterns and prognostic factors in this group remains limited, particularly in acral-predominant cohorts. We conducted a retrospective cohort study of consecutive patients with cutaneous melanoma evaluated at Taipei Veterans General Hospital between 2005 and 2025. A total of 181 patients were included and categorized into SLN-positive (n = 89) and SLN-negative (n = 92) groups for survival analysis, with further analyses of recurrence patterns and prognostic factors restricted to the SLN-negative cohort. Kaplan-Meier analysis showed significantly poorer recurrence-free survival (RFS) and overall survival (OS) in the SLN-positive group compared with the SLN-negative group (both p < 0.001). Among SLN-negative patients (mean age, 72.3 years; 88.0% acral melanoma), 25.0% developed recurrence during a median follow-up of 28.5 months, corresponding to a 5-year recurrence rate of 30.9%. Nodal recurrence was the most frequent initial pattern and tended to occur earlier than other types of recurrence. Multivariable analysis identified lower body mass index, diabetes mellitus, and ulceration as factors associated with poorer RFS, while older age, lower body mass index, and greater Breslow thickness were associated with poorer OS. These findings suggest that recurrence remains a clinically relevant concern in SLN-negative melanoma in acral-predominant Asian populations. Careful follow-up may be warranted, particularly in patients with unfavorable clinicopathologic features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.